Tycho Bismeijer

List of Publications by Year
in descending order

12 papers	**398** citations	1163117 **8** h-index	1372567 **10** g-index
13 all docs	**13** docs citations	**13** times ranked	**944** citing authors

#	Article	IF	Citations
1	Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. Npj Breast Cancer, 2021, 7, 31.	5.2	11
2	Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients. Breast, 2021, 60, 230-237.	2.2	0
3	Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression. Radiology, 2020, 296, 277-287.	7.3	37
4	Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo. Nature Communications, 2019, 10, 5034.	12.8	12
5	Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?. European Journal of Radiology, 2019, 121, 108705.	2.6	9
6	Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis. PLoS Computational Biology, 2018, 14, e1006520.	3.2	13
7	Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER+/HER2ˆ Breast Cancer. Clinical Cancer Research, 2017, 23, 6505-6515.	7.0	18
8	The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Research, 2017, 19, 99.	5.0	58
9	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	3.3	143
10	A multilevel pan-cancer map links gene mutations to cancer hallmarks. Chinese Journal of Cancer, 2015, 34, 439-49.	4.9	38
11	BRCA1â€like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Molecular Oncology, 2015, 9, 1528-1538.	4.6	54
12	Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. British Journal of Cancer, 0, , .	6.4	5